微质激活状态及其对阿尔茨海默氏症疾病的影响
Zachary Valiukas1, Kathy Tangalakis2, Vasso Apostolopoulos3
1Institute for Health and Sport, Victoria University, 70/104 Ballarat Road, Footscray VIC 3011, Australia.
The journal of prevention of Alzheimer's disease
|January 12, 2025
概括
阿尔茨海默氏病涉及有毒斑块和由微质细胞驱动的神经炎症. 调节微质以抗炎状态可能为阿尔茨海默氏症提供双重治疗,针对炎症和斑块积累.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 斑块和团.
- 微质细胞,大脑的免疫细胞,在AD病变发生过程中发挥着至关重要的作用.
- 慢性微质激活导致神经炎症,加剧AD病理.
研究的目的:
- 探索微质在阿尔茨海默病中的双重作用.
- 研究调节微质表型以获得治疗益处的潜力.
主要方法:
- 对Aβ和NFTs的微质反应的审查.
- 对促炎和抗炎微质状态的分析.
- 检查针对微质表型的治疗策略.
主要成果:
- 微质细胞最初可以清除Aβ,但在AD时会慢性激活.
- 激活的微质细胞释放炎症因素,导致神经元损伤和认知能力下降.
- 抗炎性微质激活显示神经保护作用.
结论:
- 微质表型调制为AD提供了潜在的双重治疗策略.
- 针对神经炎症与斑块病理一起,可能会减轻AD的进展.
- 恢复神经保护性微质功能是一个有前途的治疗途径.
更多相关视频
09:12Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
15.8K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
440
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
440
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161